The Global Genomics Partnering Agreements 2014-2019 report provides an understanding and access to the Genomics partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in Genomics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Genomicspartnering contract documents
Top Genomics deals by value
The Global Genomics Partnering Terms and Agreements 2014-2019 report provides an understanding and access to the Genomics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Genomicspartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Genomicstechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest Genomics, oligonucletides including aptamers agreements announced in the healthcare sectors.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all Genomics partnering deals announced since 2014 including financial terms where available including over 500 links to online deal records of actual Genomics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
The initial chapters of this report provide an orientation of Genomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Genomics dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Genomics deals since 2014. Deals are listed by headline value, signed by big pharma, most active Genomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Genomics dealmaking with a brief summary followed by a comprehensive listing of Genomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of Genomics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 lists genomics deals by technology type.
Chapter 7 provides a comprehensive and detailed review of Genomics partnering deals signed and announced since Jan 2014. The chapter is organized by specific Genomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by Genomics partnering company A-Z, deal type definitions and Genomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Genomics partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genomics technologies and products.
Global Genomics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to Genomics trends and structure of deals entered into by leading companies worldwide.
Global Genomics Partnering Terms and Agreements includes:
In Global Genomics Partnering Terms and Agreements, the available contracts are listed by:
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Global Genomics Partnering Terms and Agreements provides the reader with the following key benefits:
Table of Content
Chapter 1 – Introduction
Chapter 2 – Trends in Genomics dealmaking
2.2. Genomics partnering over the years
2.3. Most active Genomics dealmakers
2.4. Genomics partnering by deal type
2.5. Genomics partnering by therapy area
2.6. Deal terms for Genomics partnering
2.6.1 Genomics partnering headline values
2.6.2 Genomics deal upfront payments
2.6.3 Genomics deal milestone payments
2.6.4 Genomics royalty rates
Chapter 3 – Leading Genomics deals
3.2. Top Genomics deals by value
Chapter 4 – Most active Genomics dealmakers
4.2. Most active Genomics dealmakers
4.3. Most active Genomics partnering company profiles
Chapter 5 – Genomics contracts dealmaking directory
5.2. Genomics contracts dealmaking directory
Chapter 6 – Genomics dealmaking by technology type
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendix 1 – Genomics deals by company A-Z
Appendix 2 – Genomics deals by stage of development
Appendix 3 – Genomics deals by deal type
Appendix 4 – Genomics deals by therapy area
Central Nervous System
Appendix 5 –Deal type definitions
About Wildwood Ventures
Recent report titles from Current Partnering
Figure 1: Genomics partnering since 2014
Figure 2: Active Genomics dealmaking activity since 2014
Figure 3: Genomics partnering by deal type since 2014
Figure 4: Genomics partnering by disease type since 2014
Figure 5: Genomics deals with a headline value
Figure 6: Genomics deals with an upfront value
Figure 7: Genomics deals with a milestone value
Figure 8: Genomics deals with a royalty rate value
Figure 9: Top Genomics deals by value since 2014
Figure 10: Most active Genomics dealmakers since 2014
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
Make an enquiry before buying this Report
Please fill the enquiry form below.